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FGD5 amplification in breast cancer patients is associated with tumour 
proliferation and a poorer prognosis 
Purpose: Proliferation is a hallmark of cancer. Using a combined genomic approach, FGD5 
amplification has been identified as a driver of proliferation in Luminal breast cancer. We 
aimed to describe FGD5 copy number change in breast cancer, and to assess a possible 
association with tumour proliferation and prognosis. Methods: We used fluorescence in situ 
hybridization targeting FGD5 and chromosome 3 centromere (CEP3) on formalin-fixed, 
paraffin-embedded tissue from 430 primary breast cancers and 108 lymph node metastases, 
from a cohort of Norwegian breast cancer patients. We tested the association between 
FGD5 copy number status and proliferation (assessed by Ki67 levels and mitotic count) using 
Pearson’s Chi-square test, and assessed the prognostic impact of FGD5 copy number change 
by estimating cumulative risks of death and hazard ratios. Results: We identified FGD5 
amplification (defined as FGD5/CEP3 ratio ≥2 or mean FGD5/tumour cell ≥4) in 9.5% of 
tumours. Mitotic count and Ki67 levels were higher in tumours with FGD5 copy number 
increase, compared to tumours with no copy number change. After 10 years of follow-up, 
cumulative risk of death from breast cancer was higher among cases with FGD5 
amplification (48.1% (95% CI 33.8-64.7)), compared to non-amplified cases (27.7% (95% CI 
23.4-32.6)). Conclusions: FGD5 is a new prognostic marker in breast cancer, and increased 
copy number is associated with higher tumour proliferation and poorer long-term prognosis.  
 








Sustaining proliferative signaling is a hallmark of cancer [1], and the proliferation marker 
Ki67 is included in current treatment guidelines for breast cancer patients [2]. Given the 
crucial role of proliferation, identification of essential proliferation-associated genes could 
be important for prognostication and development of targeted treatment.  
Using data from two independent datasets [3, 4], and by combining gene expression 
and copy number analysis data with data from a genome-wide RNA-mediated interference 
screen on breast cancer cell lines, Gatza et al identified eight essential genes (FGD5, METTL6, 
CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) uniquely amplified in highly proliferative 
luminal (non-basal) breast tumours [5].  Amplification of four of these genes (FGD5, METTL6, 
DTX3 and MRPS23) was associated with poorer prognosis. FGD5 (Facio-Genital Dysplasia 5), 
located on the short arm of chromosome 3(3p25.1)[6], is a member of the FGD family, and 
mutations in FGD1 results in Faciogenital Dysplasia[7]. Genetic and epigenetic changes on 
the short arm of chromosome 3 have been found in epithelial tumours, including breast 
cancer [8-10]. FGD5 methylations and deletions have been identified in cervical [11], lung 
[12] and renal cell carcinomas [13]. Molecular mechanisms explaining an association 
between FGD5 amplification and tumour cell proliferation in breast cancer are unknown. 
Furthermore, an in situ assessment of FGD5 copy number change in breast cancer tissue has 
to our knowledge, not previously been performed. 
Using a cohort of Norwegian breast cancer patients, the aims of this study were 
threefold. First, to characterize FGD5 copy number change using fluorescence in situ 
hybridization (FISH) on formalin-fixed, paraffin-embedded primary tumour tissue and lymph 
node metastases; second, to assess the association of FGD5 copy number change with 
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proliferation and known prognostic factors such as histologic grade and molecular subtype, 
and third, to evaluate the association of FGD5 copy number status with prognosis. 
 
Materials and methods 
Study population 
A population-based survey for early detection of breast cancer was performed in Nord-
Trøndelag County, Norway in 1956-59, and 25,727 women born 1886-1928 were invited. 
These women were followed for breast cancer occurrence from 1961-2008 through the 
Cancer Registry of Norway. Information on date and cause of death was obtained from the 
Norwegian Cause of Death Registry. The cohort has previously been described in detail [14]. 
Briefly, 1379 incident breast cancers occurred from 1961-2008, and 909 were reclassified 
into molecular subtypes. For the present study, FISH was carried out on cases diagnosed 
after 1985 (n=453). Of these, five were excluded due to missing or insufficient tumour tissue, 
and 18 were excluded due to unsuccessful FISH. Thus, 430 cases were suitable for 
assessment of FGD5 and chromosome 3 centromere (CEP3) copy number in primary 
tumours.  
Of the 430 cases, 146 were lymph node positive at diagnosis, and tissue was available 
for 115 of these. Two cases were later excluded due to insufficient tumour tissue, and five 
were excluded due to unsuccessful FISH. Thus, 108 cases were suitable for assessment of 




All cases were previously classified according to histopathological type and grade [14], and 
tissue microarrays (TMA) were constructed using the Tissue Arrayer Minicore® 3 with TMA 
Designer2 software (Alphelys, 78370 Plaisir, France). Three 1 mm tissue cores from the 
tumour periphery were assembled in recipient blocks. Tumours were reclassified into 
molecular subtypes using immunohistochemistry (IHC) and chromogenic in situ hybridization 
(CISH) as surrogates for gene expression analysis (Supplementary Figure 1). The following 
antibodies were used: oestrogen receptor (ER), progesterone receptor (PR), human 
epidermal growth factor receptor 2 (HER2), Ki67, and basal markers cytokeratin 5 (CK5) and 
epidermal growth factor receptor (EGFR) (Supplementary Table 1) [14-16]. HER2 gene status 
was assessed using CISH.  
TMAs were constructed from lymph node metastases, and 4 μm sections were 
mounted on Superfrost+ glass slides, dried at 37°C overnight, and stored in the freezer (-
20°C). Slides were stained with HES. For immunohistochemistry, slides were heated at 60°C 
for 2 hours, and pre-treatment was carried out in a PT Link, Pre-Treatment Module for Tissue 
Specimens (Dako Denmark A/S, 2600 Glostrup, DK) with buffer (Low pH Target Retrieval 
Solution K8005) at 97°C for 20 minutes. Immunostaining for Ki67 was carried out in a 
DakoCytomationAutostainer Plus (Dako) (Supplementary Table 1). Dako REAL™EnVision™ 
Detection System with Peroxidase/DAB+, Rabbit/Mouse, code K5007, was used for 
visualization. 
FGD5 and CEP3 FISH was done according to the manufacturer’s guidelines with some 
modifications, using Dako Histology Accessory Kit K5799. After de-waxing and rehydration, 
slides from primary tumours and lymph node metastases were boiled in a microwave oven 
(10 minutes) in Pre-treatment Solution, cooled (15 minutes), and washed in Wash Buffer (3 
minutes x 2). Protein digestion of tissue samples was performed with Dako Pepsin Solution 
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at 37 ˚C (7 minutes), and then rinsed in Dako Wash Buffer (3 minutes x 2). Dehydration was 
done in ethanol (70%, 85%, 100%), for 2 minutes at each concentration, and slides were air-
dried at room temperature (10 minutes).  
FISH custom probeFGD5 (2 µL) (code G110996R-8, Agilent Technologies) and 
SureFISHChr3 CEP (2 µL) (G101065G-8, Agilent Technologies) were mixed in IQFISH Fast 
Hybridization buffer (18µL) (code G9415A, Agilent Technologies) and applied to TMA slides. 
Coverslips were applied and sealed with Dako Coverslip Sealant. Denaturation was 
performed at 80 ˚C (10 minutes) and hybridization was done at 45 ˚C for 120 minutes using 
Dako Hybridizer. Post-hybridization wash was done with Dako Stringent Wash Buffer at 
62.5˚C (10 minutes), and with Dako Wash Buffer (3 minutes x 2). Slides were air-dried at 37 
˚C (30 minutes), mounted with Dako Fluorescence Mounting Medium, and coverslipped. 
The REMARK criteria for reporting tumour marker studies were followed [17].  
 
Scoring and reporting 
FGD5 and CEP3 copy number were assessed in a fluorescence microscope (Nikon Eclipse 
90i). For each case, all available TMA spots were examined, and the proportion of tumour 
cells with >2 FGD5 copies/cell was recorded. FGD5 and CEP3 copy number in 20 non-
overlapping, well-preserved tumour cells was then recorded, and if present, tumour cells 
with FGD5 copy number increase (>2) were selected. The observer was blinded for other 
tumour data. For each case, a gene to chromosome ratio was estimated, dividing the sum of 
FGD5 copies by the sum of CEP3 copies in 20 tumour cells.  
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To assess the impact of FGD5/CEP3 ratio, cases were divided into three categories: 
1a) Cases with ≤2 FGD5 copies/nucleus in all tumour cells; 1b) Cases with >2 FGD5 
copies/nucleus in some tumour cells, and FGD5/CEP3 ratio <2; and 1c) Cases with >2 FGD5 
copies/nucleus in some tumour cells, and FGD5/CEP3 ratio ≥2.  
To assess the impact of FGD5 copy number change regardless of FGD5/CEP3 ratio, 
mean FGD5 copy number was estimated for each case. Cases were then divided into three 
categories: 2a) Cases with mean FGD5 copies/nucleus ≤2; 2b) cases with mean FGD5 
copies/nucleus >2<4; and 2c) Cases with mean FGD5 copies/nucleus ≥4. 
Finally, tumours were defined as amplified when FGD5/CEP3 ≥2 and/or mean FGD5 
≥4 (Category 3b), and as non-amplied when FGD5/CEP3 <2 and mean FGD5 <4 (Category 3a). 
 
Statistical analyses 
We used Pearson’s Chi-square test to compare proportions of patient and tumour 
characteristics across categories of FGD5 copy number status in primary tumours and lymph 
node metastases. For each category of FGD5 status in primary tumours, cumulative 
incidence of death from breast cancer was estimated, considering death from other causes a 
competing event. Gray’s test was used to test for equality between cumulative incidence 
curves. We used Cox proportional hazards models to estimate hazard ratios (HRs) of death 
from breast cancer (with 95% confidence intervals (CIs)) according to FGD5 status in primary 
tumours, censoring at time of death from other causes. Category 1a was used as the 
reference in the assessment of prognosis according to FGD5/CEP3 ratio, category 2a in 
analyses according to mean FGD5 copy number/nucleus, and category 3a in assessment of 
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prognosis according to FGD5 amplification status. Adjustments were made for other 
prognostic factors at baseline, including age (≤49, 50-59, 60-64, 65-69, 70-74, ≥75 years), 
stage (I, II, III, IV), histological grade, Ki67 (</≥ 15%), and molecular subtype. Adjustments 
were made for each variable separately, and for all variables combined. No clear violations 
of proportionality were observed in log-minus-log plots. Stata version 13.1 (Stata Corp., 




Mean age at diagnosis was 76.0 years, and mean follow-up after diagnosis was 8.0 years 
(Table 1).  
 
FGD5 in the primary tumours 
FISH analysis of breast cancer tumours revealed three distinct patterns, denoted a, b and c 
(Figure 1): Cases with a maximum of 2 FGD5 and CEP3 copies in all nuclei (a); cases with copy 
number >2 for both FGD5 and CEP3 (b), and cases with copy number >2 for FGD5, but not 
for CEP3 (c). We identified tumour cells with >2 copies of FGD5 in 308 cases (72%, Table 1). A 
total of 26 cases (6%) had FGD5/CEP3 ratio ≥2, 229 cases (53%) had a mean FGD5 copy 
number >2<4, and 32 cases (7%) had a mean copy number ≥4. By defining FGD5 
amplification as FGD5/CEP3 ratio ≥2 and/or mean copy number ≥4, 41/430 cases (9.5%) 
were found to be amplified. 
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The distribution of cells with increased FGD5 copy number was focal in many cases, 
either as dispersed single cells, or as small clusters of cells. Among all cases with FGD5 copy 
number increase, the median proportion of tumour cells with >2 FGD5 copies/cell was 10% 
(IQR 4-20%). Among amplified cases (FGD5/CEP3 ratio≥2 and/or mean FGD5≥4), the median 
proportion was higher (20%, IQR 15-40).      
FGD5 copy number increase was identified within all molecular subtypes, and 
amplified cases were found in all molecular subtypes except the 5 negative phenotype (Table 
1).  
 
FGD5 in lymph node metastases 
FISH analysis showed that the three phenotypic patterns (a, b, c) described above 
were also present in the lymph node metastases.  
We identified tumour cells with >2 copies of FGD5 in 91/108 cases (84%, Table 2) 
with lymph node metastases. FGD5 copy number increase was identified in lymph node 
metastases in 25 of the 34 cases (74%) that showed no evidence of FGD5 copy number 
increase in the primary tumour (Table 2). Of the 74 cases that had FGD5 copy number 
increase in the primary tumour, 66 (89%) also had cells with >2 FGD5 copies in the lymph 
node metastases. Only two cases (2%) had FGD5/CEP3 ratio ≥2 in the lymph node 
metastases. When cases were categorized according to mean FGD5/tumour cell irrespective 
of CEP3 copy number, 65 cases (60%) had mean FGD5/tumour cell >2<4, and 5 cases (5%) 
had mean FGD5/tumour cell ≥4. FGD5 amplification (FGD5/CEP3>2 and/or mean FGD5≥4) 
was found in 6 cases (5.5%). 
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The distribution of cells with FGD5 copy number increase was often focal and 
dispersed. Among all cases with FGD5 copy number change in the lymph nodes, the median 
proportion of tumour cells with >2 copies of FGD5 was 9% (IQR 4-20). Among amplified 
cases, the median proportion was higher (25%, IQR 20-30). 
 
FGD5, proliferation and histological grade 
Mitotic count was higher in amplified, compared to non-amplified tumours (29% vs. 21% in 
highest quartile, p<0.001, Table 1). Ki67 levels were also higher in amplified tumours (54% 
vs. 36% had Ki67≥15%, p= 0.026). Cases with FGD5 amplification had a higher proportion of 
grade 3 tumours, compared to non-amplified cases (59% vs. 28%, p<0.001). 
We found no clear association between FGD5 copy number increase and Ki67 levels 
in lymph node metastases (Supplementary Table 2). 
 
FGD5 and prognosis 
Prognosis according to FGD5/CEP3 ratio 
For cases without FGD5 copy number increase (Category 1a), cumulative risk of death from 
breast cancer after 10 years of follow-up was 23.7% (95% CI 16.9-32.7) (Table 3, Figure 2). 
For Category 1b and 1c, the corresponding cumulative risks of death were higher (30.5% 
(95% CI 25.4-36.5) and 47.0% (95% CI 29.9-67.8), respectively). 
Comparing rates of death between categories, we found higher rates among patients 
in Category 1b and 1c, compared to Category 1a (age-adjusted HRs of 1.4 (95% CI 0.9-2.1) 
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and 2.6 (95% CI 1.3-4.9), respectively). Adjustments for grade, stage, Ki67, and molecular 
subtypes gave similar results, regardless of whether adjustments were made for each 
variable separately, or for all variables combined.  
 
Prognosis according to mean FGD5 copy number/tumour cell 
Cumulative risk of death from breast cancer increased with increasing mean FGD5 
copies/nucleus (Table 3, Figure 2). For cases with mean FGD5/cell ≤2 (Category 2a), 
cumulative risk after 10 years of follow-up was 22.6% (95% CI 16.8-29.9). For cases with 
mean FGD5/cell >2<4 (Category 2b), the corresponding risk was 32.1% (95% CI 26.3-38.8), 
and for patients with mean FGD5/tumour cell ≥4 (Category 2c), risk of death was 49.6% (95% 
CI 33.3-68.5). 
Comparing rates of death, we found higher rates among patients in Category 2b and 
2c, compared to Category 2a (age-adjusted HRs of 1.6 (95% CI 1.1-2.4) and 2.6 (95% CI 1.4-
4.6), respectively). Adjustments for grade, stage, Ki67, and molecular subtype gave similar 
results for category 2b, both after adjustment for each variable separately, and for all 
variables combined. For category 2c, the HR after adjustment for all factors combined was 
attenuated to 1.6 (95% CI 0.8-3.0).  
 
Prognosis according to FGD5 amplification status 
For non-amplified cases, cumulative risk of death from breast cancer after 10 years of 
follow-up was 27.7% (95% CI 23.4-32.6) (Table 4, Figure 2). For amplified cases (FGD5/CEP3 
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ratio ≥2 and/or mean FGD5 ≥4), the corresponding cumulative risk of death was higher 
(48.1% (95% CI 33.8-64.7)). 
We found higher rates of death from breast cancer among amplified cases, compared 
to non-amplified cases (age-adjusted HR 2.0 (95% CI 1.2-3.2). After adjustments for age, 
grade, stage, Ki67, and molecular subtype, the HR was attenuated to 1.4 (95% CI 0.8-2.3).  
 
FGD5 and prognosis within molecular subtypes of breast cancer 
For Luminal A cases, cumulative risk of death 10 years after diagnosis was higher for cases 
with FGD5 copy number increase, compared to cases without (Supplementary Table 3, 
Supplementary Figure 2). For category 1a, cumulative risk of death 10 years after diagnosis 
was 20% (95% CI 12.1-32.1), and for category 1c, the corresponding risk was 27.7% (95% CI 
9.9-63.7). Category 1b had a better prognosis than category 1a five years after diagnosis. For 
category 2a, cumulative risk after 10 years was 16.1% (95% CI 10.0-25.4), and for category 
2c, the corresponding risk was 34.8% (95% CI 16.1-64.9).  
FGD5 amplified Luminal A cases had a higher risk of death from breast cancer than 
non-amplified cases. The cumulative risk of death estimates 10 years after diagnosis were 
34.3% (95% CI 17.0-61.2) and 21% (95% CI 15.9-27.4), respectively (Supplementary Table 4).  
Comparing rates of death between categories, we found a poorer prognosis with 
increasing FGD5/CEP3 ratio and with increasing mean FGD5, and for amplified cases 
compared to non-amplified cases (Supplementary Table 3 and 4). For the remaining 





We identified FGD5 copy number increase in primary tumours and lymph node metastases 
in a large proportion of breast cancer patients. FGD5 amplification in the primary tumour 
was associated with higher proliferation, and poorer survival. 
Using FGD5/CEP3 ratio ≥2 and/or FGD5 copy number ≥4 as a definition of gene 
amplification, 41 cases (9.5%) were amplified. We are not aware of other studies where 
FGD5 gene amplification status in breast cancer has been assessed by FISH. However, in the 
TCGA data set, 15% of cases were found to be FGD5 amplified by copy number analysis, 
whereas in the METABRIC dataset 3% were amplified [5].  
In accordance with Gatza et al, we found that FGD5 amplification was associated with 
higher proliferation and poorer prognosis. In our study, FGD5 amplified cases had a higher 
mitotic count and higher Ki67 levels than non-amplified cases. The prognosis of patients with 
FGD5 copy number increase was poorer both when analyses were based on FGD5/CEP3 ratio 
and on mean FGD5 copy number. Comparing rates of death between amplified and non-
amplified cases, we found that associations were attenuated and less clear after 
adjustments for grade, Ki67 levels, stage and molecular subtype. The question is whether 
adjustments for these factors are justified. If FGD5 amplification is a driver of proliferation, 
as suggested by Gatza et al [5], then consequences of FGD5 amplification could, at least in 
part, be mediated through grade, stage and Ki67 levels. Although valuable from a 
prognostication perspective, adjustments for these factors could mask the overall role of 
FGD5 as a driver of breast cancer progression [18].  
In the study by Gatza et al, FGD5 was uniquely amplified in highly proliferative 
luminal tumours. Subtyping was based on gene expression analysis, and luminal tumours 
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were defined as all tumours that were not Basal [5, 19]. We categorized tumours into six 
different subtypes based on IHC and ISH as surrogates for gene expression analysis, and 
found amplifications in all subtypes, except the 5 negative phenotype. Even though studies 
have shown good correlation between subtyping by gene expression and surrogate markers, 
classification by these two methods are not identical [20-22]. Furthermore, focal FGD5 copy 
number increase may be easier to identify with an in situ technique such as FISH, than with 
copy number analysis. This could explain why we, contrary to Gatza, identified FGD5 copy 
number increase in all molecular subtypes.  
We found some Luminal A tumours with FGD5 copy number increase. According to 
our subtyping algorithm, Luminal A tumours have Ki67 levels <15%, and are thus not highly 
proliferative. In this cohort, we have found that Ki67 levels in TMAs are generally lower than 
in the corresponding whole sections (unpublished data), a finding that is in accordance with 
others [23]. It is therefore possible that some of our Luminal A cases are misclassified 
Luminal B tumours. Furthermore, 5/18 (28%) of the FGD5 amplified Luminal A tumours were 
histological grade 3. According to the recent St. Gallen Expert Consensus, histological grade 3 
Luminal A tumours could represent misclassified Luminal B tumours [2].  
Using FISH, we were able to study FGD5 gene- and CEP3 copy number status while 
observing the morphology of breast cancer tumours. Thus, only invasive epithelial tumour 
cells were assessed, and the distribution and proportion of amplified cells could be 
evaluated. Amplification has been defined as a copy number increase in a segment of the 
genome [24], however there is no established gold standard as to how gene amplification 
should be defined. According to current HER2 treatment guidelines [25], both 
HER2/centromere 17 (CEP17) ratio and HER2 copy number (regardless of ratio), are taken 
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into account [26, 27]. FGD5 is a new marker with no available guidelines for assessment. By 
using a centromere probe in addition to the gene probe, we could assess the prognostic 
value of both FGD5/CEP3 ratio and of mean FGD5 copy number. When present, cells with 
FGD5 copy number increase were selected for assessment, even when such changes were 
seen only focally. One could argue that the overall mean copy numbers of FGD5 and CEP3 
would be a better way to report each tumour. However, this approach could mask the 
potential prognostic impact of the focal changes identified in this study. 
FGD5 amplification status in primary tumours and lymph node metastases was 
assessed in TMAs, comprising three 1 mm tissue cores from each case. When present, 
amplifications were only identified in a proportion of tumour cells. Previous studies have 
shown good correlation between TMA and whole sections for other markers [28-30], but it is 
likely that intratumoural heterogeneity may have led to an underestimation of cases with 
gene amplification in the present study. The presence of FGD5 amplified cells in the lymph 
nodes of some patients without findings in the primary tumour support this hypothesis. 
Thus, the observed associations of FGD5 amplification with tumour characteristics and 
prognosis may underestimate the true effect of FGD5 copy number increase. Still, a high 
number of comparisons were made, and with a limited number of amplified cases, the CIs 
were relatively wide. 
Molecular mechanisms explaining the association between FGD5 amplification and 
proliferation and prognosis are unknown. However, FGD5 is expressed in hematopoietic 
stem cells [31] and in vascular endothelial cells, and it has been found to regulate the 
proangiogenic effect of vascular endothelial growth factor (VEGF), including network 
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formation, cell-matrix interaction, endothelial cell permeability, movement, proliferation 
and adhesion [32, 33].  
We were able to reproduce the main findings from Gatza’s study in our cohort of 
breast cancer patients, with a mean age at diagnosis of 76 years. It has been suggested that 
proliferation is a stronger prognostic factor in younger breast cancer patients [34]. 
Therefore, amplification of FGD5, a gene associated with proliferation, could be of greater 
relevance in prognostication of younger breast cancer patients. It is necessary to validate our 
findings in a cohort of younger breast cancer patients. 
In conclusion, FGD5 has been identified as an essential gene in breast cancer 
proliferation, making it valuable as a prognostic marker, and a potential target for 
treatment. Using FISH in a large, well-described cohort of breast cancer patients, we have 
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Fig. 1 a) Breast cancer cell without increased numbers of FGD5 or CEP3 signals.  b) Breast 
cancer cell with increased numbers of FGD5 and CEP3 signals. c) Breast cancer cell with 
increased numbers of FGD5 signals  
Fig. 2 Cumulative incidence of death from breast cancer according to FGD5 copy number 
status. a) FGD5 copy number status based on FGD5/CEP3 ratio (Gray’s test: p=0.018). b) 
FGD5 copy number status based on mean FGD5 (Gray’s test: p=0.0013). c)  FGD5 









    
Table 1. Characteristics of the study population. 
 
 Categories defined by FGD5/CEP3 ratio Categories defined by mean FGD5 




Max. 2 FGD5 
copies/cell 
(1a) 







 >2<4  
(2b) 











N (%) 430 (100) 122 (28) 282 (66) 26 (6)  169 (39) 229 (53) 32 (7)  389 41  
Mean age at diagnosis 
(SD) 
76.0 (7.7) 75.4 (7.4) 76.2 (7.8) 76.2 (8.2)  75.3 (7.3) 76.2 (8.0) 77.8 (7.5)  
75.9 (7.7) 76.7 (8.0)  
Mean follow-up after 
diagnosis (SD) 
8.0 (5.8) 8.4 (5.9) 8.1 (5.9) 6.2 (4.6)  9.0 (6.1) 7.6 (5.8) 6.1 (4.0)  
8.2 (5.9) 6.1 (4.4)  
Deaths from BC (%) 139 (32) 30 (25) 96 (34) 13 (50)  41 (24) 82 (36) 16 (50)  119 (31) 20 (49)  
Deaths from other 
causes (%) 
179 (42) 53 (43) 118 (42) 8 (42)  77 (46) 93 (41) 9 (28)  
167 (43) 12 (29)  
Grade (%)    
   I 53 (12) 17 (14) 34 (12) 2 (8) p=0.003 25 (15) 26 (11) 2 (6) p=0.001 50 (13) 3 (7) P<0.001 
   II 243 (57) 82 (67) 151 (54) 10 (38)  107 (63) 125 (55) 11 (34)  229 (59) 14 (34)  
   III 134 (31) 23 (19) 97 (34) 14 (54)  37 (22) 78 (34) 19 (59)  110 (28) 24 (59)  
Lymph node metastasis    
   Yes 146 (34) 45 (37) 91 (32) 10 (38) p=0.859 57 (34) 75 (33) 14 (44) p=0.579 129 (33) 17 (41) P=0.348 
   No 198 (46) 57 (47) 129 (46) 12 (46)  78 (46) 107 (47) 13 (41)  181 (47) 17 (41)  
   Unknown 
histopathologyc 
86 (20) 20 (16) 62 (22) 4 (15)  34 (20) 47 (21) 5 (16)  
79 (20) 7 (17)  
Tumour size    
   ≤2 cm 226 (53) 68 (56) 144 (51) 14 (54) p=0.977 101 (60) 109 (48) 16 (50) p=0.515 206 (53) 20 (49) P=0.623 
   >2 cm, ≤5 cm  86 (20) 26 (21) 55 (20) 5 (19)  33 (20) 46 (20) 7 (22)  77 (20) 9 (22)  
   >5 cm 10 (2) 3 (2) 7 (2) 0  4 (2) 6 (3) 0  10 (3) 0   
   Uncertain, but >2 cm 48 (11) 12 (10) 33 (12) 3 (12)  14 (8) 30 (13) 4 (13)  42 (11) 6 (15)  
   Uncertain 60 (14) 13 (11) 43 (15) 4 (15)  17 (10) 38 (17) 5 (16)  54 (14) 6 (15)  
Stage    
   1 195 (45) 56 (46) 126 (45) 13 (50) p=0.868 84 (50) 98 (43) 13 (41) p=0.639 177 (46) 18 (44) P=0.332 
   2 195 (45) 55 (45) 130 (46) 10 (38)  72 (43) 109 (48) 14 (44)  179 (46) 16 (39)  








   4 16 (4) 3 (2) 11 (4) 2 (8)  4 (2) 10 (4) 2 (6)  13 (3) 3 (7)  
Molecular subtype (%)    
   Luminal A 238 (55) 72 (59) 155 (55) 11 (42) p=0.098 101 (60) 122 (53) 15 (47) p=0.241 220 (57) 18 (44) P=0.250 
   Luminal B (HER2-) 102 (24) 27 (22) 68 (24) 7 (27)  39 (23) 54 ((24) 9 (28)  27 (7) 3 (7)  
   Luminal B (HER2+) 30 (7) 6 (5) 22 (8) 2 (8)  8 (5) 20 (9) 2 (6)  91 (23) 11 (27)  
   HER2 type 20 (5) 3 (2) 14 (5) 3 (12)  4 (2) 14 (6) 2 (6)  16 (4) 4 (10)  
   5NP 10 (2) 7 (6) 3 (1) 0  7 (4) 3 (1) 0  10 (3) 0  
   BP 30 (7) 7 (6) 20 (7) 3 (12)  10 (6) 16 (7) 4 (13)  25 (6) 5 (12)  
Ki67 high/low (%)    
   Ki67<15% 268 (62) 84 (69) 173 (61) 11 (42) p= 0.03 114 (67) 138 (60) 16 (50) p=0.112 249 (64) 19 (46) P=0.026 
   Ki67 ≥15% 162 (38) 38 (31) 109 (39) 15 (58)  55 (33) 91 (40) 16 (50)  140 (36) 22 (54)  
Mitoses/10 HPF, 
median (IQR p25, p75) 
4.5 (1, 12) 2 (0, 8) 5 (1, 12) 9.5 (5, 17)  3 (1, 9) 5 (1, 12) 9 (5, 14)  
4 (1, 11) 9 (5, 16)  
Mitoses/10HPF, quartiles (%)    
   ≤ 1 125 (29) 48 (39) 73 (26) 4 (15) p=0.012 60 (36) 61 (27) 4 (13) p=0.001 119 (31) 6 (15) P<0.001 
   >1, ≤ 4.5 90 (21) 26 (21) 62 (22) 2 (8)  36 (21) 52 (23) 2 (6)  88 (23) 2 (5)  
   >4.5, ≤12 121 (28) 28 (23) 82 (29) 11 (42)  44 (26) 59 (26) 18 (56)  100 (26) 21 (51)  
   >12 94 (22) 20 (16) 65 (23) 9 (35)  29 (17) 57 (25) 8 (25)  82 (21) 12 (29)  
Abbreviations: Max.= maximum, SD= standard deviation, BC= breast cancer, HER2= human epidermal growth factor receptor 2, 5NP= 5 negative phenotype, BP= Basal phenotype, HPF= high 
power fields, IQR= interquartile range. 
aCells with >2 FGD5 copies present, and FGD5/CEP3 ratio<2.  bCells with >2 FGD5 copies present, and FGD5/CEP3 ratio≥2. c Includes cases where histopathological examination was done, but 
reports were not available, and cases where no axillary lymph nodes were removed. 
 
Table 2. FGD5 status in primary tumours and lymph node metastases according to FGD5/CEP3 ratio and mean FGD5 
 FGD5/CEP3 ratio, primary tumours 







FGD5/CEP3 ratio, lymph nodes 
   Max. 2 FGD5 copies/cell  9 (26) 7 (11) 1 (11) 17 p= 0.06 
   FGD5/CEP3<2a 25 (74) 57 (88) 7 (78) 89  
   FGD5/CEP3≥2b 0 1 (2) 1 (11) 2  
   Total 34 65 9 108  
 Mean FGD5/tumour cell, primary tumours 
Mean FGD5≤2 (2a) Mean FGD5>2<4 (2b) Mean FGD5≥4 (2c) Total Chi2 
Mean FGD5/tumour cell, lymph nodes 
   Mean FGD5≤2 26 (62) 11 (21) 1 (8) 38 p<0.001 
   Mean FGD5>2<4 16 (38) 41 (77) 8 (62) 65  
   Mean FGD5≥4 0 1 (2) 4 (31) 5  
   Total 42 53 13 108  
Abbreviation: Max.= maximum. 








Table 3. Absolute and relative risks of death from breast cancer according to FGD5/CEP3 ratio and mean FGD5/ tumor cell 
    FGD5/CEP3 ratio, primary tumors Mean FGD5/tumor cell, primary tumors 












Cum. risk after 5 years (%) (95% CI) 15.3 (9.9-23.2) 22.0 (17.5-27.3) 30.8 (16.7-52.2) 14.6 (10.0-21.0) 23.0 (18.0-29.0) 35.3 (21.3-54.6) 
Cum. risk after 10 years (%) (95% CI) 23.7 (16.9-32.7) 30.5 (25.4-36.5) 47.0 (29.9-67.8) 22.6 (16.8-29.9) 32.1 (26.3-38.8) 49.6 (33.3-68.5) 
HRc adjusted for age (95% CI) 1.0 1.4 (0.9-2.1) 2.6 (1.3-4.9) 1.0 1.6 (1.1-2.4) 2.6 (1.4-4.6) 
HRc adjusted for age, grade, stage, Ki67 (95% CI) 1.0 1.4 (0.9-2.1) 2.5 (1.3-4.9) 1.0 1.5 (1.0-2.1) 1.7 (0.9-3.1) 
HRc adjusted for age, grade, stage, Ki67, and 
molecular subtype (95% CI) 
1.0 1.4 (0.9-2.1) 2.5 (1.2-4.9) 1.0 1.4 (1.0-2.1) 1.6 (0.8-3.0) 
Abbreviations: Cum.=Cumulative, CI= Confidence interval, HR=Hazard ratio 
aCells with >2 FGD5 copies present, and FGD5/CEP3 ratio<2.  bCells with >2 FGD5 copies present, and FGD5/CEP3 ratio≥2. cHazard ratios (HR) from Cox regression 



















Table 4. Absolute and relative risks of death from breast cancer according to FGD5 amplification status. 





Cum. risk after 5 years (%) (95% CI) 18.8 (15.3-23.1) 37.2 (24.4-54.0) 
Cum. risk after 10 years (%) (95% CI) 27.7 (23.4-32.6) 48.1 (33.8-64.7) 
HRa adjusted for age (95% CI) 1.0 2.0 (1.2-3.2) 
HRa adjusted for age, grade, stage, Ki67 (95% CI) 1.0 1.4 (0.9-2.3) 
HRa adjusted for age, grade, stage, Ki67, and 
molecular subtype (95% CI) 
1.0 1.4 (0.8-2.3) 
Abbreviations: Cum.=Cumulative, CI= Confidence interval, HR=Hazard ratio. 











Supplementary Table 1: Primary antibodies used in molecular subtyping of breast cancer 
Antibody Clone Manufacturera Concentration of antibody Dilution 
ER SP1 Cell marque 33 mg/ml 1:100 
PR 16 Novocastra 360 mg/l 1:400 
HER2 CB11 Novocastra 3.9 g/l 1:640 
Ki67 MIB1 Dako 35 mg/l 1:100 
CK5 XM26 Novocastra 50 mg/l 1:100 
EGFR 2-18C9 Dako Ready to use No dilution 
Abbreviations: ER= Oestrogen receptor, PR= Progesterone receptor, HER2= Human epidermal 
growth factor receptor, CK5= Cytokeratin 5, EGFR= Epidermal growth factor receptor  
aFull name and address of manufacturers: Cell Marque, Rocklin, United States. NovoCastra 















Supplementary Table 2. FGD5 status and Ki67 levels  in lymph nodes 
 FGD5/CEP3 ratio, lymph nodes Mean FGD5/tumor cell, lymph nodes 














Ki67, lymph nodes (%) 
   Ki67<15% 9 (53) 47 (53) 0 (0) 56 p=0.334 22 (58) 33 (51) 1 (20) 56 p= 0.27 
   Ki67≥15% 8 (47) 42 (47) 2 (100) 52  16 (42) 32 (49) 4 (80) 52  
   Total   17 89 2 108  38 65 5 108  
Abbreviations: Max.= maximum  
aCells with >2 FGD5 copies present, and FGD5/CEP3 ratio<2.  bCells with >2 FGD5 copies present, and FGD5/CEP3 ratio≥2. 
 
 
Supplementary Table 3. Absolute and relative risks of death from breast cancer according to FGD5/CEP3 ratio and mean FGD5/ tumor cell in Luminal A cases. 
    FGD5/CEP3 ratio, primary tumours Mean FGD5, primary tumours 













Cum. risk after 5 years (%) (95% CI) 13.2 (7.1-23.8) 11.2 (7.1-17.4) 18.2 (4.9-55.3) 10.3 (5.6-18.2) 11.7 (7.1-18.9) 26.8 (11.0-56.6) 
Cum. risk after 10 years (%) (95% CI) 20.0 (12.1-32.1) 22.6 (16.5-30.5) 27.7 (9.9-63.7) 16.1 (10.0-25.4) 25.4 (18.2-34.7) 34.8 (16.1-64.9) 
HRc adjusted for age (95% CI) 1.0 1.3 (0.7-2.3) 2.0 (0.7-6.2) 1.0 1.9 (1.1-3.4) 3.2 (1.2-8.3) 
HRc adjusted for age, grade, stage, Ki67 (95% 
CI) 
1.0 1.2 (0.7-2.3) 2.2 (0.7-6.7) 1.0 1.7 (0.9-3.1) 2.9 (1.1-7.6) 
Abbreviations: Cum.=Cumulative, CI= Confidence interval, HR= hazard ratio.  
aCells with >2 FGD5 copies present, and FGD5/CEP3 ratio<2.  bCells with >2 FGD5 copies present, and FGD5/CEP3 ratio≥2. cHazard ratios (HR) from Cox regression 
for the entire follow-up period. 
 
 
Supplementary Table 4. Absolute and relative risks of death from breast cancer according to FGD5 
amplification status in Luminal A cases. 





Cum. risk after 5 years (%) (95% CI) 10.7 (7.3-15.7) 27.8 (12.7-54.5) 
Cum. risk after 10 years (%) (95% CI) 21 (15.9-27.4) 34.3 (17.0-61.2) 
HRa adjusted for age (95% CI) 1.0 2.1 (0.9-4.7) 
HRa adjusted for age, grade, stage, Ki67 (95% CI) 1.0 2.1 (0.9-4.8) 
Abbreviations: Cum.=Cumulative, CI= Confidence interval, HR=Hazard ratio. 




Breast Cancer Research and Treatment 
FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis 
Marit Valla, Monica Jernberg Engstrøm, Borgny Ytterhus, Åse Kristin Skain Hansen, Lars Andreas Akslen, Lars Johan Vatten, Signe Opdahl, Anna 
Mary Bofin. 
 
Corresponding author: Marit Valla 
E-mail: marit.valla@ntnu.no 









Supplementary Fig. 1 Algorithm for molecular subtyping. Abbreviations: ER= Ostrogen receptor, PR= Progesterone receptor, HER2= Human epidermal 
growth factor receptor 2, CK5= Cytokeratin 5, EGFR= Epidermal growth factor receptor 
 
Supplementary Fig. 2 Cumulative incidence of death from Luminal A breast cancer according to FGD5 copy number status. a) FGD5 copy number status 
based on FGD5/CEP3 ratio (Gray’s test: p=0.57). b) FGD5 copy number status based on mean FGD5 (Gray’s test: p=0.064). c) FGD5 amplification status 
(Gray’s test: p=0.079) 
 
